Physician profile
Kerry Schaffer
NPI 1306283197
$20,773.20
in general payments reported to CMS, 2019-2025
12 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $14K · 2023: $6,001 · 2024: $143 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,640 · Travel and Lodging: $1,077 · Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,640.00 |
| Travel and Lodging | $1,077.01 |
| Food and Beverage | $887.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14,081.48 | 2021-2023 | |
| Genzyme Corporation | $5,461.69 | 2022 | |
| Janssen Biotech, INC. | $350.61 | 2021-2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $331.68 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $145.61 | 2025 | Darzalex, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $114.91 | 2023 | Opdivo |
| Progenics Pharmaceuticals, INC. | $113.19 | 2024 | |
| Myovant Sciences INC. | $108.20 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $65.83 | 2025 | Lynparza |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.